KU Leuven spin-off AstriVax raises € 30 million seed capital to build vaccine platform
Retrieved on:
Thursday, August 25, 2022
Energy, CEO, KU Leuven, Technology, BEL20, Private banking, Virus, Medtech, Vaccine, Flanders, Care, Euronext, Patient, BNP Paribas Fortis, Biohub, University, Digital transformation, Ackermans & van Haaren, Committee on European Affairs and Oversight of the European Funds, Student, List of life sciences, Public, History, Intellectual property, European Investment Fund, Industry, Development, PMV, EIF, Rabies, Investment, KU, European Commission Investment Plan for Europe, EFSI, Growth, Health, Venture, Thuja, Cornerstone, Doctor of Philosophy, Heart, Infection, Real estate, IPO, Physician, Alexander von Humboldt German International School Montreal, Union, Health care, Climate, VIB, Communications satellite, Financial services, Pharmaceutical industry, European
Closing on 30 million, AstriVax has raised the largest amount of seed capital in the history of spin-offs linked to Belgium-based university KU Leuven.
Key Points:
- Closing on 30 million, AstriVax has raised the largest amount of seed capital in the history of spin-offs linked to Belgium-based university KU Leuven.
- Leuven, Belgium, 25 August 2022 Closing on 30 million, AstriVax has raised the largest amount of seed capital in the history of KU Leuven spin-offs.
- The company will also continue to build its highly innovative, first-in-class plug-and-play vaccine platform based on the ground-breaking work of co-founders Professor Johan Neyts and Kai Dallmeier, PhD, from the KU Leuven Rega Institute.
- From 2005 to 2021, KU Leuven invested 21.7 million in its spin-off companies, and 1.46 billion of external capital was raised.